Harnessing real-world data to improve healthcare management

Quality of care

Drug use

Costs of illness

  • News

    PELyon has been awarded by the The Respiratory Effectiveness Group for the best oral abstract on “Therapeutic ratios predict asthma control in the Astrolab cohort” that was presented at the REG Summit 2018 on 22nd – 24th March 2018.

    List of winners More information

  • News

    PELyon will attend the 34rd International Congress for PharmacoEpidemiology that will take place from the 22th to the 26th of August in Prague, Czech Republic. It is organised by the International Society for PharmacoEpidemiology.

    Plus d'informations

  • News

    We are happy to welcome Clarisse MARCHAL and Déborah WALTHER, who will bring their knowledge and expertise in PELyon. Clarisse as project Manager and Déborah as Data analyst.
    More information
  • News

    PELyon attended the “Adelf Emois” Days 2018 (CPLF) that took place on March 29-30 in Montpellier, France. These days have been organized since several years thanks to joint efforts of an Association of French Epidemiologists and an Association “Evaluation, Management, Organization, Information, Health”.

    Dr Van Ganse and Belhassen presented results extracted from the Astrolab Study on therapeutic ratios and asthma control, as well as frequency at which asthma patients will look for their prescriptions.

    Plus d'informations

Presentation of PELyon
Created in 2000 by Doctor Eric Van Ganse, Associated Professor of Clinical Pharmacology and Public Health Expert, PELyon conducts a broad range of research projects, with emphasis on pharmacoepidemiological studies, burden/cost of illness, adherence and Comparative Effectiveness Research.

PELyon consists of Medical Doctors, Epidemiologists, Project Managers, Data Managers and Statisticians, who combine their skills and experience to address current health-related issues.

PELyon aims at helping decision-makers (health authorities, biomedical industries, and healthcare settings) by offering tools that will enable them to choose between different therapeutic strategies or public health programmes.